The Food and Drug Administration (FDA) has approved Heplisav-B for the prevention of infection caused by all known subtypes of hepatitis B virus.
Hepatitis B and hepatitis C may increase mortality risks in HIV patients.
Aspirin therapy is associated with a reduced risk of hepatitis B virus-related hepatocellular carcinoma.
The American Academy of Pediatrics recommends that the first dose of the hepatitis B vaccine should be given within the first 24 hours of life.
Telbivudine administered during early and middle pregnancy prevented hepatitis B transmission from mother to infants in all participants receiving antiviral treatment.
HIV, hepatitis B, and hepatitis C infections are more common among individuals with severe mental illness.
The universal vaccination against hepatitis B virus infection prevented non-Hodgkin lymphoma in adolescents.
Pregnant women with a high hepatitis B viral load who receive tenofovir have a reduced risk for passing the virus to their child.
The updated guidelines include substantial changes in the management of hepatitis B based on the latest scientific evidence.
Statin use decreased rates of decompensation in patients with liver cirrhosis due to HBV and HCV infections and in patients with alcohol-induced cirrhosis.
Aggressive testing, diagnosis, treatment, and prevention methods, such as needle exchange for those who inject drugs, are some of the options that the NASEM explored to target hepatitis elimination.
Patients with HIV receiving antiretroviral treatment have a higher risk of non-Hodgkin's lymphoma with HBV and HCV coinfection.
The FDA issues a warning about the risk of hepatitis B virus reactivation among patients taking direct-acting antivirals to treat hepatitis C infections.
A patient's positive hepatitis B results were overlooked for 7 years.
A new hepatology rotation increased the mean comfort level for managing several liver diseases.
Biologic agents associated with high risk of hepatitis B virus flares in patients with psoriasis or rheumatoid arthritisNovember 14, 2015
The use of biologic agents in treatment of patients rheumatoid arthritis or psoriasis is associated with a significant risk of heptatis B flares.